Basis: Trailing twelve months (TTM). Source: stored company filings and market data; unavailable inputs remain N/A.
Is the EBITDA margin high or low?
The EBITDA margin of 6.31% is 25% below its 5-year average of 8.41%, around the middle of its 5-year range (-559.88%–302.72%).
91.14% below its 12-month average of 71.24%.
Reported quarterly EBITDA margin; no daily interpolation. Q2 FY2026 (2026-06-30): 12.74%.
EBITDA MARGIN
6.31%
EBITDA MARGIN AVG TTM
71.24%
EBITDA MARGIN AVG 3Y
-107.86%
EBITDA MARGIN AVG 5Y
8.41%
EBITDA MARGIN AVG 10Y
N/A
EBITDA MARGIN AVG 15Y
N/A
EBITDA MARGIN AVG 20Y
N/A
CURRENT VS TTM AVG
-91.14%
CURRENT VS 3Y AVG
+105.85%
CURRENT VS 5Y AVG
-24.99%
CURRENT VS 10Y AVG
N/A
CURRENT VS 15Y AVG
N/A
CURRENT VS 20Y AVG
N/A
Definitive Healthcare Corp.
Market Cap
$104.26M
EBITDA Margin
6.31%
TTM Avg
71.24%
3Y Avg
-107.86%
5Y Avg
8.41%
Market Cap
$104.68M
EBITDA Margin
N/A
TTM Avg
N/A
3Y Avg
N/A
5Y Avg
N/A
Market Cap
$103.14M
EBITDA Margin
28.85%
TTM Avg
28.85%
3Y Avg
28.85%
5Y Avg
28.85%
Market Cap
$102.75M
EBITDA Margin
-5221.43%
TTM Avg
-5221.43%
3Y Avg
-3887.65%
5Y Avg
-3386.47%
Market Cap
$106.52M
EBITDA Margin
-624817.90%
TTM Avg
-624817.90%
3Y Avg
-624817.90%
5Y Avg
-624817.90%
Market Cap
$106.93M
EBITDA Margin
-893.25%
TTM Avg
-695.97%
3Y Avg
-642.31%
5Y Avg
-567.69%
Market Cap
$106.96M
EBITDA Margin
-4735.97%
TTM Avg
-4735.97%
3Y Avg
-4735.97%
5Y Avg
-4735.97%
Market Cap
$106.98M
EBITDA Margin
5.60%
TTM Avg
2.28%
3Y Avg
0.00%
5Y Avg
-2.15%
Market Cap
$107.09M
EBITDA Margin
-6164.17%
TTM Avg
-4620.17%
3Y Avg
-2654.54%
5Y Avg
-2163.85%
| NAME | MARKET CAP | EBITDA MARGIN | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| Definitive Healthcare Corp. (DH) | $104.26M | 6.31% | 71.24% | -107.86% | 8.41% |
| Polaryx Therapeutics, Inc. Common Stock (PLYX)vs › | $104.68M | N/A | N/A | N/A | N/A |
| Black Diamond Therapeutics, Inc. (BDTX)vs › | $103.14M | 28.85% | 28.85% | 28.85% | 28.85% |
| Anixa Biosciences, Inc. (ANIX)vs › | $102.75M | -5221.43% | -5221.43% | -3887.65% | -3386.47% |
| Immunic, Inc. (IMUX)vs › | $106.52M | -624817.90% | -624817.90% | -624817.90% | -624817.90% |
| Vivani Medical, Inc. (VANI)vs › | $106.93M | -893.25% | -695.97% | -642.31% | -567.69% |
| Outlook Therapeutics, Inc. (OTLK)vs › | $106.96M | -4735.97% | -4735.97% | -4735.97% | -4735.97% |
| Cumberland Pharmaceuticals Inc. (CPIX)vs › | $106.98M | 5.60% | 2.28% | 0.00% | -2.15% |
| Corbus Pharmaceuticals Holdings, Inc. (CRBP)vs › | $107.09M | -6164.17% | -4620.17% | -2654.54% | -2163.85% |
| The Joint Corp. (JYNT)vs › | $101.36M | 1.47% | 3.45% | 8.31% | 9.97% |
Gross Margin
71.7%
EBITDA Margin
6.3%
Operating Margin
-8.5%
Net Margin
-72.3%
Formula: EBITDA Margin = (EBITDA / Revenue) × 100
Why EBITDA Margin matters:
EBITDA Margin = EBITDA / Revenue
EBITDA margin measures operating profitability before interest, taxes, depreciation, and amortization as a percentage of revenue.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
| DATE | EBITDA MARGIN |
|---|---|
| 2026-06-30 | 12.74% |
| 2026-03-31 | 15.04% |
| 2025-12-31 | 302.72% |
| 2025-09-30 | 8.95% |
| 2025-06-30 | 16.74% |
| 2025-03-31 | -288.84% |
| 2024-12-31 | -138.76% |
| 2024-09-30 | -338.62% |
| 2024-06-30 | -559.88% |
| 2024-03-31 | -5.62% |
| 2023-12-31 | 4.43% |
| 2023-09-30 | -432.23% |
| 2023-06-30 | 1.16% |
| 2023-03-31 | 1.14% |
| 2022-12-31 | 3.55% |
| 2022-09-30 | 5.45% |
| 2022-06-30 | 7.14% |
| 2022-03-31 | 7.35% |
| 2021-12-31 | 1.57% |
| 2021-09-30 | 25.74% |
| 2021-06-30 | 20.80% |
| 2021-03-31 | 33.92% |
| 2020-12-31 | 24.70% |
| 2020-09-30 | 46.44% |
| 2020-06-30 | 43.17% |
| 2020-03-31 | 41.87% |
